By Kimberly Capone, PhD, Chief Science Officer, Vaginal Biome Science, Good Clean Clinical Care
Vaginal dryness, vulvar burning, tissue sensitivity, and pain with penetration can persist during breast-cancer treatment and long into survivorship. These symptoms may be grouped together as genitourinary syndrome of menopause (GSM), but they do not necessarily call for the same intervention.
For clinicians, the more useful question is not simply whether a patient has vaginal dryness. It is where the discomfort occurs, what is contributing to it, and which treatment approach best addresses that particular problem.
Breast-cancer history adds another layer to treatment selection, but it does not eliminate the opportunity to provide meaningful symptom relief.
Why breast-cancer treatment changes vulvovaginal health
Estrogen helps maintain vaginal and vulvar tissue thickness, elasticity, lubrication, and the local vaginal environment. Chemotherapy, ovarian suppression or removal, and endocrine therapies can alter estrogen production or signaling and contribute to GSM symptoms. Aromatase inhibitors reduce estrogen synthesis, while tamoxifen acts differently by blocking estrogen receptors in breast tissue. These distinctions matter when considering treatment.
The location of symptoms matters just as much. Predominantly internal dryness is a different clinical presentation from tenderness localized to the vestibule or pain related to pelvic-floor muscle tension. More than one factor may be present, and treating dryness alone may not address them all.
Nonhormonal moisture support is an important starting point
For patients with a history of estrogen-dependent breast cancer, nonhormonal approaches are generally the first step. Vaginal moisturizers help manage ongoing dryness, while lubricants help reduce friction during sexual activity. Hyaluronic acid and vaginal vitamin E are among the nonhormonal options discussed in clinical guidance.
Good Clean Rx offers two BiomeNourish™ Moisture + Comfort formulations: a hyaluronic acid and vitamin E cream and a sodium hyaluronate and vitamin E vaginal suppository. The cream provides flexibility for internal vaginal or external vulvar/vestibular application as directed; the suppository offers an internal vaginal option. Both allow clinicians to consider not only the ingredients, but also where support is needed and which dosage form a patient prefers.
Pain at the vaginal opening may need a different strategy
Some patients continue to experience pain with penetration even when dryness improves. Localized vestibular tenderness, for example, may benefit from an approach that is different from routine vaginal moisturizing.
In a randomized trial involving breast-cancer survivors with severe dyspareunia, targeted application of aqueous lidocaine to the vestibule reduced pain with penetration. This supports evaluating where pain originates rather than assuming all discomfort is a lubrication problem.
Good Clean Rx includes external lidocaine-containing creams combined with phenylephrine for temporary relief of vulvar or vestibular pain and burning. These are external treatments, not intravaginal moisturizers. When pelvic-floor dysfunction is also contributing, pelvic-floor physical therapy may be an important part of care.
When local hormonal therapy enters the discussion
Nonhormonal care may not fully address persistent GSM symptoms. Current ACOG guidance allows consideration of certain low-dose vaginal estrogen treatments after an inadequate response to nonhormonal approaches, using shared decision-making. For patients taking aromatase inhibitors, that discussion should include the patient, gynecologist, and oncologist.
Good Clean Rx also makes clinician-directed estradiol with vitamin E, estriol, and vaginal DHEA formulations available for individualized treatment planning. These options differ in hormonal activity, dose, and available evidence; compounded strengths should not automatically be equated with the low-dose products evaluated in clinical guidance. DHEA is a hormonal therapy, not a hormone-free substitute. The patient's cancer history and current endocrine treatment remain central to selection.
Why the formulation matters, too
Vulvovaginal tissue affected by estrogen depletion can be particularly sensitive. For local treatment, the active ingredient is only one part of the decision. The application site, dosage form, and formulation carrying that ingredient also deserve attention.
BiomeNourish™ cream base is a proprietary pH-balanced, iso-osmolar cream base designed specifically for vulvar and vaginal tissue compatibility. This reflects a core principle behind Good Clean Rx: local care should consider the biology and condition of the tissue receiving the treatment, not just the medication being delivered.
A broader toolkit for clinicians through Good Clean Rx
Good Clean Rx brings these care options into one prescriber platform. Clinicians can explore nonhormonal moisture and comfort formulations, local pain-relief creams, and selected hormone therapies when appropriate, with access to individualized compounding and pharmacy fulfillment. Quantitative vaginal microbiome testing is also available when overlapping or recurrent infectious symptoms make additional evaluation appropriate.
The goal is not to apply one protocol to every breast-cancer survivor. It is to give clinicians more ways to match treatment to the symptom, the tissue, and the patient's history.
Providers can explore the current formulary and register for Good Clean Rx through the platform link below. Registered providers receive my in-depth clinical education series through the provider platform, with expanded coverage of the evidence, treatment selection, formulation considerations, and practical clinical guidance behind each monthly topic.
Explore the Good Clean Rx prescriber platform: https://www.goodcleanrx.com/.
Selected References
ACOG. Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer. Clinical Consensus. 2021; reaffirmed 2024. Source
AUA/SUFU/AUGS. Genitourinary Syndrome of Menopause Guideline. 2025. Source
Agrawal S, et al. A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause. 2024. Source
Goetsch MF, et al. A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial. J Clin Oncol. 2015. Source
DailyMed. INTRAROSA (prasterone) prescribing information. Source
Compounded medications are not FDA-approved. Evidence for a studied therapy or formulation does not establish identical safety, absorption, or effectiveness for every compounded product. Clinical use is individualized.
Vaginal Biome Science (VBS), the Institute's sister company, is a pioneering biotechnology leader dedicated to revolutionizing women's vaginal healthcare through scientific innovation.
Vaginal conditions
Beyond the Formulary: Helping Clinicians Put Good Clean Rx Into Practice
Good Clean Rx expands the clinical toolkit for vulvovaginal care, but knowing what treatments are available is only the beginning. The new IVH Clinical Education Series explores the biology, clinical reasoning, and practical considerations behind less familiar therapeutic options.
